SWS
NBIX icon

SYSTM Wealth Solutions’s Neurocrine Biosciences NBIX Stock Holding History

SYSTM Wealth Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,224
Closed -$731K – 511
2023
Q1 		$731K Buy
7,224
+2,354
+48% +$245K 0.11% 220
2022
Q4 		$582K Buy
+4,870
New +$570K 0.07% 313

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SYSTM Wealth Solutions's NBIX Position: Q2 2023 in Review

SYSTM Wealth Solutions sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 7,224 shares — an estimated $731K sold.

SYSTM Wealth Solutions first reported a position in NBIX in Q4 2022 and held it in 2 quarters. The position peaked at $731K in Q1 2023. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • SYSTM Wealth Solutions reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • SYSTM Wealth Solutions sold 7,224 Neurocrine Biosciences shares in Q2 2023, an estimated $731K.
  • SYSTM Wealth Solutions first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 2 quarters.
  • SYSTM Wealth Solutions's Neurocrine Biosciences position peaked at $731K in Q1 2023.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on SYSTM Wealth Solutions's 13F filing for Q2 2023, filed 14 Aug 2023.